Boehringer Ingelheim to acquire STEAG microParts GmbH


Boehringer Ingelheim is to acquire the microtechnology specialist STEAG microParts GmbH from STEAG AG, Essen, Germany. STEAG microParts, established in 1990, is a worldwide leader in microsystem technology with headquarters at the hub of technology in Dortmund, Germany.

STEAG microParts' core product is the innovative Respimat® Soft MistTM Inhaler which was co-developed together with Boehringer Ingelheim. This novel medicinal inhaler, which generates a slow-moving long-lasting soft mist through purely mechanical means, allows for excellent penetration of the lungs. Respimat® Soft MistTM Inhaler offers all patients with asthma or COPD (chronic-obstructive airways disease) effective medication in precise doses.

"The acquisition of STEAG microParts fits very well into our production strategy," explained Dr Hans-Jürgen Leuchs, responsible within the Boehringer Ingelheim Board of Managing Directors for production and technology. "We see Respimat® Soft MistTM Inhaler as the inhalation device of the future; it is to be tested in clinical studies successively with different respiratory products. We thank STEAG microParts for the excellent cooperation in recent years and now look forward to having full control of the entire production chain following the acquisition. In addition, the expertise in development and production at STEAG microParts, especially in microsystem technology, will be an excellent supplement to our development activities in the field of innovative Drug Delivery".

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics